ZIM Laboratories Limited Listing on BSE Main Board

Mumbai, June 10: ZIM Laboratories Limited (ZIM) has been listed on the BSE Main Board on June 8, 2018. The book value price of ZIM was Rs 160 per equity share.

Anwar Daud, Chairman & Managing Director, told mediapersons here recently that ZIM is amongst the few global companies to have developed and commercialized the oral film technology, besides also being the first Indian company to manufacture multi-layer thin films that contain more than one API on a single thin strip.

Describing ZIM Laboratories as a unique R&D-centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS), he said ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines and the company listing on BSE on June 8 had a price discovery as per trading on the bourses.

Promoted by Technocrat Dr. Anwar Daud, the company has a unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries.

Since inception in 1989, ZIM made a significant mark as a ‘pharma innovator’ by penetrating newer areas of pharmaceutical technology and business, while establishing itself as a preferred healthcare solution provider in the field of New Drug Delivery Systems, Daud said, adding that ZIM has developed 19 products and commercialized 13 of them within 3 years. ZIM has received 24 DCGI product approvals & is awaiting 14 in India and 13 product approvals overseas.

Headquartered in the industrial belt of Nagpur city of Central India, ZIM is an EU-GMP & WHO-GMP Certified and ISO 9001:2008 accredited company supported by a team of professionals and capacity to meet large requirements for different market segments, he said while the noting that the company is engaged in research and development, manufacturing, distribution and marketing of oral solid dosage forms such as tablets, capsules, pellets, multi particulate systems, dry syrups, directly compressible granules, taste masked powders, granules and orally disintegrating strips.

Related Posts

About The Author